CD38 and hepatocellular carcinoma: Similar to Innate Pharma’s ANKETTM platform, Cytovia Therapeutics has leveraged its FLEX-NK platform to engineer CYT-303 and CYT-338 NKCEs, targeting the CD38 antigen for hematological malignancies and GPC-3 for hepatocellular carcinoma (95, 97).